Trial Information

Summary: Study of the use of peripheral blood stem cells for allogeneic transplantation (PBSCT) in patients with advanced hematological malignancies at increased risk of relapse or transplant-related mortality

Allogeneic marrow transplantation is potentially curative therapy for the hematoligical malignancies, but several conditions are associated with a high risk of relapse and transplant-related mortality. Compared to conventional allogeneic marrow transplantation, PBSCT has the potential advantages that it will promote a graft versus malignancy (GVM) effect, thus reducing the chance of relapse, and that it will facilitate engraftment, meaning that blood counts will recover faster than with standard allogeneic transplantation. this may reduce infectious and hemorrhagic risk and thus reduce transplant-related mortality. In this study, patients with high-risk conditions will be transplanted with stem cells from the donor's peripheral blood rather than bone marrow. This will ideally reduce rates of infection and hemorrhage as well as length of hospital stay, cost, and transplant-related mortality.

Two categories of patients will be eligible:

• 1
  • CML in advanced phase
    
  • AML in relapse or 2nd (or later) remission,
    
  • ALL in relapse or 1st (or later) remission
    
  • MDS (chronic myelomonocytic leukemia, refractory anemia with excess blasts),
    
  • Mulitple MyelomaR
  • CLL, or
    
  • Lymphoma (resistant disease or relapse after previous autograft).
• 2. The patient is an allogeneic transplant candidate with relatively 'low risk' malignant conditions (e.g., CML in chronic phase, acute leukemia in first remission) and has a suitalbe family member donor unable or unwilling to undergo a bone marrow harvest.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:10 AM